Targeted Genetics Corporation - Investor Relations Home

» Investor Relations Home
Corporate Governance
Stock Information
Press Releases
Event Calendar
SEC Filings
Financial Reports
Analysts
Webcasts/Presentations
Contact Information
E-mail Alerts
Information Request

Company Overview

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative therapies for the prevention and treatment of diseases with significant unmet medical need. Targeted Genetics is based in Seattle, Washington and has been public since May 1994 and its stock trades on the NASDAQ Capital Market under the ticker symbol TGEN.

Recent News

More News >>

Date	Title
06/01/10	Targeted Genetics Corporation Reports Fourth Quarter and Full Year 2009 Financial Results
05/30/10	Targeted Genetics' Partner Celladon Corporation Reports Positive Phase 2 Clinical Trial Data at Heart Failure Association Annual Meeting
04/28/10	Targeted Genetics' Partner, Celladon Corporation, Reports Achievement of Primary Endpoints in Phase II Clinical Trial of MYDICAR(R) for the Treatment of Advanced Heart Failure
04/16/10	Targeted Genetics Reports Board Changes

Upcoming Events

More Events >>

There are currently no events scheduled.

Featured Report

2008 10-K

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Targeted Genetics posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

TGEN: NASDAQ

$0.40
- 0.01 (down 2.44%)
Minimum 20 Minute Delay

Intraday High
$0.41

Intraday Low
$0.40

Volume
19,300

Last Trade
09/02/10 3:54 p.m. ET